1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7)
    Meeting Abstract

    Westin, J.; Locke, F. L.; Dickinson, M.; Ghobadi, A.; Elsawy, M.; van Meerten, T.; Miklos, D. B.; Ulrickson, M.; Perales, M. A.; Farooq, U.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term results of a phase 2 trial of crenolanib combined with 7+3 chemotherapy in adults with newly diagnosed FLT3 mutant AML
    Meeting Abstract

    Wang, E. S.; Goldberg, A. D.; Walter, R. B.; Collins, R.; Stone, R. M.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI
    Meeting Abstract

    Usmani, S. Z.; Martin, T. G.; Berdeja, J. G.; Jakubowiak, A. J.; Agha, M. E.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A. M.; Munshi, N. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Analysis of peripheral neuropathy (PN) using clinician- and patient-reported outcomes (ClinRO and PRO) in the POLARIX study
    Meeting Abstract

    Trneny, M.; Fogliatto, L.; Gardner, F. P.; Flinn, I. W.; Larouche, J. F.; Haioun, C.; Albendea, M. A. C.; Goto, H.; Hajek, R.; Salles, G. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Impact of clonal hematopoiesis on tumor control following radiation therapy
    Meeting Abstract

    Tao, J.; Setton, J.; Vela, P. S.; Safonov, A. M.; Comen, E. A.; Braunstein, L. Z.; Reis-Filho, J. S.; Riaz, N.; Powell, S. N.; Levine, R. L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy (SELECT AML-1)
    Meeting Abstract

    Stein, E.; De Botton, S.; Pigneux, A.; McMahon, C.; Ball, B.; Borthakur, G.; Eghtedar, A.; Kambhampati, S.; Tache, J.; Wang, E. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Impact of bone marrow involvement in patients with peripheral T-cell lymphoma undergoing autologous stem cell transplant
    Meeting Abstract

    Stuver, R.; Mazloom, A.; Ganesan, N.; Horwitz, S. M.; Moskowitz, A. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase I/II study of prexasertib in combination with irinotecan in patients with relapsed/refractory desmoplastic small round cell tumor and rhabdomyosarcoma
    Meeting Abstract

    Slotkin, E. K.; Mauguen, A.; Ortiz, M. V.; Dela Cruz, F. S.; O'Donohue, T.; Kinnaman, M. D.; Meyers, P. A.; Wexler, L. H.; Rodriguez, S.; Avutu, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas
    Meeting Abstract

    Schuster, S. J.; Huw, L. Y.; Bolen, C. R.; Assouline, S. E.; Bartlett, N. L.; Budde, L. E.; Matasar, M. J.; Koeppen, H.; Piccione, E. C.; Wilson, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy
    Meeting Abstract

    Sallman, D. A.; Foran, J. M.; Watts, J. M.; Stein, E.; De Botton, S.; Fathi, A. T.; Prince, G. T.; Stone, R. M.; Patel, P. A.; Roboz, G. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save